Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from NexgenRx ( (TSE:NXG) ).
NexgenRx Inc. reported strong 2025 year-end results, with revenue rising 8.84% to $14.93 million and organic growth of 12% in administration and transaction revenue. EBITDA increased to $3.35 million and net income to $1.29 million, while the company maintained a solid cash position of $4.78 million after paying $1.30 million in dividends.
Management highlighted that disciplined execution, deeper client relationships and ongoing development initiatives underpinned the performance, reinforcing the resilience of its recurring-revenue business model. With a healthy sales pipeline and focus on new product solutions, NexgenRx positions itself for continued growth and sustained free cash flow generation, supporting long-term value for shareholders and clients in the benefits administration market.
More about NexgenRx
NexgenRx Inc. is a Canadian independent full-service third-party administrator and technology solutions provider focused on health benefits administration. The company offers proprietary front-end eligibility, enrolment, hour bank and mobile access tools, combined with advanced claims adjudication and a full provider network, delivering its solutions to plan sponsors through a cost-effective SaaS model.
Average Trading Volume: 28,352
Technical Sentiment Signal: Buy
Current Market Cap: C$23.82M
See more data about NXG stock on TipRanks’ Stock Analysis page.